Literature DB >> 2914369

Measurement of autoimmune response against collagen types I, III, and IV by enzyme-linked immunosorbent assay, and its application in infective endocarditis.

M L De Buyzere1, I K De Scheerder, J R Delanghe, J H Robbrecht, D L Clement, R J Wieme.   

Abstract

In these enzyme-linked immunosorbent assays for determination of autoantibodies (IgG, IgM) against collagen type I (ACA I), III (ACA III), and IV (ACA IV), we use commercially available antigen preparations. Inhibition curves showed limited cross-reactivity between these different collagen preparations, the major interference being observed after addition of collagen type III in the ACA I procedures. Imprecision (CVs) for high- and low-titer samples ranged between 1.5% and 7.9% (within-run) and 5.5% and 12.7% (between-run) for ACA I, between 2.2-8.7% and 4.5-10.7% for ACA III, and between 1.3-5.9% and 7.4-11.6% for ACA IV. Significantly increased humoral immune response against collagen types I and III (P less than 0.001) could be demonstrated during the first month of infective endocarditis. In contrast, only borderline increases, however constant, of autoimmune response against basement-membrane collagen (ACA IV) were noticed during 90 days of follow-up.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914369

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome.

Authors:  José Pardos-Gea; Josefina Cortés-Hernández; Jesus Castro-Marrero; Eva Balada; José Ordi-Ros
Journal:  Clin Rheumatol       Date:  2017-03-10       Impact factor: 2.980

2.  Rethinking Molecular Mimicry in Rheumatic Heart Disease and Autoimmune Myocarditis: Laminin, Collagen IV, CAR, and B1AR as Initial Targets of Disease.

Authors:  Robert Root-Bernstein
Journal:  Front Pediatr       Date:  2014-08-19       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.